Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer
-
Published:2023-07-14
Issue:14
Volume:149
Page:12597-12604
-
ISSN:0171-5216
-
Container-title:Journal of Cancer Research and Clinical Oncology
-
language:en
-
Short-container-title:J Cancer Res Clin Oncol
Author:
Thangarajah Fabinshy,Busshoff Jana,Salamon Janina,Pruss Marie-Sandrine,Lenz Caroline,Morgenstern Bernd,Hellmich Martin,Schlößer Hans Anton,Lenz Maximilian,Domröse Christian,Mallmann Michael R.,Mallmann Peter,Weiß Jonathan,Franzen Fabian,Merkelbach-Bruse Sabine,Binot Elke,Eich Marie-Lisa,Büttner Reinhardt,Schultheis Anne Maria,Alidousty Christina
Abstract
Abstract
Purpose
More than 99% of cervical cancers and up to 40% of vulvar cancers are human papillomavirus (HPV) related. HPV 16 and 18 are the most relevant subtypes. Novel technologies allow the detection of minimal amounts of circulating cell-free HPV DNA (ccfHPV-DNA). The aim of this study was to evaluate ccfHPV-DNA assessed by droplet digital PCR (ddPCR) as a biomarker for molecular therapy monitoring in early, advanced, relapsed and metastatic HPV-driven cervical and vulvar cancer.
Methods
Inclusion criteria of the study were histologically proven HPV 16/18-driven cervical and vulvar cancer with first diagnosed disease, newly diagnosed recurrence, or progression of disease. Blood samples were taken pre- and post-therapeutically. Circulating cell-free HPV DNA was quantified using ddPCR and the results were correlated with clinical data.
Results
The mean copy number of ccfHPV-DNA was 838.6 (± 3089.1) in pretreatment and 2.3 (± 6.4) in post-treatment samples (p < 0.05). The copy number of ccfHPV-DNA increased with higher FIGO stages (p < 0.05), which are commonly used for clinical staging/assessment. Furthermore, we compared the distribution of copy numbers between T-stage 1 versus T-stage 2/3. We could show higher copy number level of ccfHPV-DNA in T-stage 2/3 (p < 0.05).
Conclusions
Therapy monitoring with determination of ccfHPV-DNA by ddPCR with a small amount of plasma reflects response to therapy and appears feasible for patients in advanced cancer stages of cervical and vulvar cancer. This promising tool should be examined as marker of therapy monitoring in particular in novel HPV-directed therapies.
Funder
Marga und Walter Boll-Stiftung Universitätsklinikum Essen
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference33 articles.
1. Bakker NAM, Rotman J, van Beurden M, Zijlmans HJMAA, van Ruiten M, Samuels S, Nuijen B, Beijnen J, de Visser K, Haanen J, Schumacher T, de Gruijl TD, Jordanova ES, Kenter GG, van den Berg JH, van Trommel NE (2021) HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial. J Immunother Cancer. https://doi.org/10.1136/JITC-2021-002547 2. Burd EM (2003) Human papillomavirus and cervical cancer. Clin Microbiol Rev 16:1–17. https://doi.org/10.1128/CMR.16.1.1-17.2003 3. Cabel L, Bonneau C, Bernard-Tessier A, Héquet D, Tran-Perennou C, Bataillon G, Rouzier R, Féron JG, Fourchotte V, Le Brun JF, Benoît C, Rodrigues M, Scher N, Minsat M, Legrier ME, Bièche I, Proudhon C, Sastre-Garau X, Bidard FC, Jeannot E (2021) HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer. ESMO Open. https://doi.org/10.1016/J.ESMOOP.2021.100154/ATTACHMENT/E8AD2CAE-3052-48D3-967C-FEDE35532C23/MMC3.DOCX 4. Chera BS, Kumar S, Beaty BT, Marron D, Jefferys S, Green R, Goldman EC, Amdur R, Sheets N, Dagan R, Hayes DN, Weiss J, Grilley-Olson JE, Zanation A, Hackman T, Blumberg JM, Patel S, Weissler M, Tan XM, Parker JS, Mendenhall W, Gupta GP (2019) Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clin Cancer Res 25:4682–4690. https://doi.org/10.1158/1078-0432.CCR-19-0211 5. Cheung TH, Yim SF, Yu MY, Worley MJ, Fiascone SJ, Chiu RWK, Lo KWK, Siu NSS, Wong MCS, Yeung ACM, Wong RRY, Chen ZG, Elias KM, Chung TKH, Berkowitz RS, Wong YF, Chan PKS (2019) Liquid biopsy of HPV DNA in cervical cancer. J Clin Virol 114:32–36. https://doi.org/10.1016/J.JCV.2019.03.005
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|